Thermo Fisher Scientific (TMO) Stock
Global leader in laboratory instruments and consumables. Here's the price, business snapshot, and what's worth knowing about Thermo Fisher Scientific in July 2026.
Thermo Fisher Scientific (TMO) is a global leader in laboratory instruments, consumables, and services that support scientific research, healthcare, and industrial applications. With a diversified portfolio across life‑sciences research tools, analytical instruments, specialty diagnostics and laboratory services, the company benefits from recurring consumables and service revenue as well as long‑term demand driven by R&D, healthcare spending and public health needs. Its scale and distribution reach help it serve pharmaceutical, biotech, academic and clinical customers worldwide. Investors should note strengths such as a broad product mix, exposure to steady R&D trends and potential margin resilience from high‑margin consumables, but also risks including integration of acquisitions, regulatory scrutiny, and sensitivity to capital spending cycles. Market cap and valuation can fluctuate; this summary is educational and not personal investment advice. Consider how the company fits your risk profile and investment horizon before making decisions.
Why It’s Moving
TMO Stock Surges as Analysts Pivot to Clario Acquisition and AI-Driven Lab Demand for 2026
- The pending close of the Clario acquisition is expected to unlock mid-2026 revenue synergies, with analysts projecting a 21% to 42% upside as margin expansion accelerates.
- Earnings sentiment is bolstered by the company's forward P/E compressing to 17.5x, marking it as a valuation leader compared to its 5-year average and signaling strong investor confidence in future cash flows.
- Healthcare sector trends show a surge in AI-integrated diagnostic requests, positioning Thermo Fisher's lab equipment portfolio as a critical infrastructure for the next wave of data-driven medical research.
TMO Stock Surges as Analysts Pivot to Clario Acquisition and AI-Driven Lab Demand for 2026
- The pending close of the Clario acquisition is expected to unlock mid-2026 revenue synergies, with analysts projecting a 21% to 42% upside as margin expansion accelerates.
- Earnings sentiment is bolstered by the company's forward P/E compressing to 17.5x, marking it as a valuation leader compared to its 5-year average and signaling strong investor confidence in future cash flows.
- Healthcare sector trends show a surge in AI-integrated diagnostic requests, positioning Thermo Fisher's lab equipment portfolio as a critical infrastructure for the next wave of data-driven medical research.
When is the next earnings date for Thermo Fisher Scientific (TMO)?
Thermo Fisher Scientific (TMO) is estimated to release its next earnings report on July 22, 2026, covering the second quarter of fiscal year 2026. This date aligns with the company's historical reporting pattern for the Q2 period, which typically occurs in the latter half of July. The upcoming announcement will provide critical financial results for the three-month period ending June 30, 2026. Investors should monitor official company filings for any potential adjustments to this projected timeline.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Thermo Fisher's stock with a target price of $619.49, indicating strong growth potential.
Financial Health
Thermo Fisher Scientific is performing well with strong revenue, cash flow, and profit margins.
Dividend
Thermo Fisher Scientific's low dividend yield of 0.34% indicates limited income potential for investors seeking dividends. If you invested $1000 you would be paid $3.40 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring TMO
Food Safety Stocks: What's Next After Costco Lawsuit
A recent lawsuit against Costco regarding salmonella in its rotisserie chicken has intensified focus on food safety across the grocery industry. This creates a potential investment opportunity in companies that provide testing, diagnostics, and supply chain verification services.
Published: 15 February 2026
Explore BasketFood Safety Investing: The Next Chapter Unfolds
Recent recalls of baby formula by Danone and other major brands, traced back to a single contaminated ingredient supplier, have exposed significant risks in the global supply chain. This situation creates a potential investment opportunity in companies focused on food safety, testing, and alternative brands with more secure sourcing.
Published: 24 January 2026
Explore BasketU.S. Drug Manufacturing | Multi-Billion Investment Push
Johnson & Johnson is the latest major drugmaker to lower U.S. prices in exchange for tariff exemptions, joining a broad industry trend. This government-led initiative is sparking a multi-billion dollar investment wave into domestic manufacturing, creating a significant opportunity for companies supporting the U.S. pharmaceutical supply chain.
Published: 10 January 2026
Explore BasketPharma Reshoring Explained | Manufacturing Investment
Major pharmaceutical firms have signed agreements with the U.S. government to lower drug prices in exchange for tariff exemptions and other concessions. This move is expected to drive over $150 billion in new domestic R&D and manufacturing investments, creating opportunities for U.S.-based life sciences and industrial supply chain companies.
Published: 21 December 2025
Explore BasketLife Sciences Brazil | Clinical Trial Stock Exposure
Brazil's expanding role in global medical research may increase local access to cutting-edge treatments and stimulate economic growth. This basket provides exposure to the theme through US and EU-listed companies that supply critical services and infrastructure for clinical trials in the region.
Published: 3 November 2025
Explore BasketHealthcare Innovation Brazil Investment Theme 2025
Brazil is ramping up investment to enhance its healthcare quality and access, creating significant opportunities for innovation. This basket offers exposure to key US and EU-listed companies providing the medical devices, software, and biotech research driving this transformation.
Published: 30 October 2025
Explore BasketActivist Sparks Life Science Shakeup
Activist investor Engine Capital is pushing for a sale of life-sciences company Avantor after taking a significant stake. This move could spark a wave of M&A across the life-sciences supply industry, creating opportunities for competitor firms and other potential acquisition targets.
Published: 11 August 2025
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: 23 July 2025
Explore BasketDiagnostic Takeover Targets
This carefully selected group of stocks features innovative diagnostic companies that could become acquisition targets following recent takeover interest in the sector. Professional analysts have identified these companies for their unique technologies and established market positions in a consolidating healthcare landscape.
Published: 15 July 2025
Explore BasketEmpire Builders
These companies are led by visionaries who excel at growing through smart acquisitions. Our analysts have carefully selected businesses with proven ability to buy competitors, integrate them successfully, and build lasting market power.
Published: 17 June 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: 6 May 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring Consumables Revenue
Consumables and reagents can create predictable revenue and support margins, though demand can vary with research funding and market cycles.
Global Scientific Reach
A broad international footprint serves diverse customers from pharma to academia, offering resilience but also exposure to regional regulation and economic shifts.
Innovation and Scale
Product innovation and acquisitions expand the addressable market, yet integration and execution risks can affect near‑term results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
